These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 30786836

  • 1. Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer.
    Shao B, Wang X, Zhang L, Li D, Liu X, Song G, Cao H, Zhu J, Li H.
    Technol Cancer Res Treat; 2019 Jan 01; 18():1533033819828709. PubMed ID: 30786836
    [Abstract] [Full Text] [Related]

  • 2. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
    Kassem NM, Makar WS, Kassem HA, Talima S, Tarek M, Hesham H, El-Desouky MA.
    Asian Pac J Cancer Prev; 2019 Sep 01; 20(9):2749-2755. PubMed ID: 31554373
    [Abstract] [Full Text] [Related]

  • 3. Circulating microRNA-based screening tool for breast cancer.
    Frères P, Wenric S, Boukerroucha M, Fasquelle C, Thiry J, Bovy N, Struman I, Geurts P, Collignon J, Schroeder H, Kridelka F, Lifrange E, Jossa V, Bours V, Josse C, Jerusalem G.
    Oncotarget; 2016 Feb 02; 7(5):5416-28. PubMed ID: 26734993
    [Abstract] [Full Text] [Related]

  • 4. Circulating microRNAs in plasma as early detection markers for breast cancer.
    Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, Junkermann H, Schneeweiss A, Burwinkel B.
    Int J Cancer; 2013 Apr 01; 132(7):1602-12. PubMed ID: 22927033
    [Abstract] [Full Text] [Related]

  • 5. Circulating miR-195 as a Therapeutic Biomarker in Turkish Breast Cancer Patients.
    Cecene G, Ak S, Eskiler GG, Demirdogen E, Erturk E, Gokgoz S, Polatkan V, Egeli U, Tunca B, Tezcan G, Topal U, Tolunay S, Tasdelen I.
    Asian Pac J Cancer Prev; 2016 Apr 01; 17(9):4241-4246. PubMed ID: 27797225
    [Abstract] [Full Text] [Related]

  • 6. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z, Zhang L, Yu G, Sun Z, Wang T, Tian X, Duan X, Zhang C.
    Cancer Chemother Pharmacol; 2020 Dec 01; 86(6):761-772. PubMed ID: 33068176
    [Abstract] [Full Text] [Related]

  • 7. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
    Liu B, Su F, Chen M, Li Y, Qi X, Xiao J, Li X, Liu X, Liang W, Zhang Y, Zhang J.
    Hum Pathol; 2017 Jun 01; 64():44-52. PubMed ID: 28412211
    [Abstract] [Full Text] [Related]

  • 8. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers.
    Chen W, Cai F, Zhang B, Barekati Z, Zhong XY.
    Tumour Biol; 2013 Feb 01; 34(1):455-62. PubMed ID: 23238818
    [Abstract] [Full Text] [Related]

  • 9. MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression.
    Tang X, Jin L, Cao P, Cao K, Huang C, Luo Y, Ma J, Shen S, Tan M, Li X, Zhou M.
    Oncotarget; 2016 Apr 26; 7(17):23668-83. PubMed ID: 26993770
    [Abstract] [Full Text] [Related]

  • 10. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue.
    Mar-Aguilar F, Luna-Aguirre CM, Moreno-Rocha JC, Araiza-Chávez J, Trevino V, Rodríguez-Padilla C, Reséndez-Pérez D.
    Asia Pac J Clin Oncol; 2013 Mar 26; 9(1):53-9. PubMed ID: 22898264
    [Abstract] [Full Text] [Related]

  • 11. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
    Zuberi M, Mir R, Das J, Ahmad I, Javid J, Yadav P, Masroor M, Ahmad S, Ray PC, Saxena A.
    Clin Transl Oncol; 2015 Oct 26; 17(10):779-87. PubMed ID: 26063644
    [Abstract] [Full Text] [Related]

  • 12. Expression Analysis of miR-29b in Malignant and Benign Breast Tumors: A Promising Prognostic Biomarker for Invasive Ductal Carcinoma With a Possible Histotype-Related Expression Status.
    Papachristopoulou G, Papadopoulos EI, Nonni A, Rassidakis GZ, Scorilas A.
    Clin Breast Cancer; 2018 Aug 26; 18(4):305-312.e3. PubMed ID: 29422258
    [Abstract] [Full Text] [Related]

  • 13. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
    Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lübbe K, Schem C, Fasching PA, Mau C, Pantel K, Schwarzenbach H.
    Breast Cancer Res Treat; 2014 Aug 26; 147(1):61-8. PubMed ID: 25086636
    [Abstract] [Full Text] [Related]

  • 14. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
    McAnena P, Tanriverdi K, Curran C, Gilligan K, Freedman JE, Brown JAL, Kerin MJ.
    BMC Cancer; 2019 May 10; 19(1):436. PubMed ID: 31077182
    [Abstract] [Full Text] [Related]

  • 15. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
    Xing AY, Wang B, Li YH, Chen X, Wang YW, Liu HT, Gao P.
    Pathol Oncol Res; 2021 May 10; 27():1609753. PubMed ID: 34257614
    [Abstract] [Full Text] [Related]

  • 16. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer.
    Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, Luo H.
    PLoS One; 2012 May 10; 7(4):e34210. PubMed ID: 22523546
    [Abstract] [Full Text] [Related]

  • 17. Study of microRNAs-21/221 as potential breast cancer biomarkers in Egyptian women.
    Motawi TM, Sadik NA, Shaker OG, El Masry MR, Mohareb F.
    Gene; 2016 Sep 30; 590(2):210-9. PubMed ID: 26827795
    [Abstract] [Full Text] [Related]

  • 18. Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.
    Li G, Yao L, Zhang J, Li X, Dang S, Zeng K, Zhou Y, Gao F.
    Tumour Biol; 2016 Jun 30; 37(6):7481-91. PubMed ID: 26678891
    [Abstract] [Full Text] [Related]

  • 19. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
    Wang B, Li J, Sun M, Sun L, Zhang X.
    IUBMB Life; 2014 May 30; 66(5):371-7. PubMed ID: 24846313
    [Abstract] [Full Text] [Related]

  • 20. MiR-4728-3p could act as a marker of HER2 status.
    Li H, Zhou X, Zhu J, Cheng W, Zhu W, Shu Y, Liu P.
    Cancer Biomark; 2015 May 30; 15(6):807-14. PubMed ID: 26406406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.